Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND

Next Previous
Trial Profile

A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Tafasitamab (Primary) ; Cyclophosphamide; Doxorubicin; Granulocyte colony-stimulating factors; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms First-MIND
  • Sponsors MorphoSys

Most Recent Events

  • 14 Mar 2023 Status changed from active, no longer recruiting to completed.
  • 13 Dec 2022 Results of ultrasensitive MRD profiling predicts outcomes in diffuse large b cell lymphoma after frontline therapy with tafasitamab in combination with lenalidomide and R-CHOP, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 10 Dec 2022 According to a MorphoSys media release, Greg S. Nowakowski, M.D., Professor of Medicine and Oncology at the Mayo Clinic, is a lead investigator for the firstMIND trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top